Norway-based medical diagnostics company Gentian Diagnostics AS (Euronext Growth Oslo:GENT) said on Friday that its SARS-CoV-2 antibody test is moving to the next development phase.
The project has progressed from the proof-of-concept phase to the project initiation and optimisation phase. Gentian has established an official project plan with an approved budget and a dedicated project team, and the timeline to launch is set for the fourth quarter of 2021.
Gentian's SARS-CoV-2 antibody test is designed to offer the first assay on high-throughput open-access clinical chemistry platforms, supporting COVID-19 vaccination efforts and aiding in community management by the determination of immunisation status.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD